Charles J. Davidson
Corporate Officer/Principal bij Vicuron Pharmaceuticals LLC
Oorsprong van het eerstegraads netwerk van Charles J. Davidson
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Charles J. Davidson via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
University of Oxford | College/University | Doctorate Degree | |
The University of Manchester | College/University | Undergraduate Degree | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Lederle Laboratories
Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Glaxo Group Research Ltd. | Corporate Officer/Principal | ||
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Biotechnology | Director/Board Member | |
Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd. | Corporate Officer/Principal | ||
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
Rhodes College | College/University | Undergraduate Degree | |
Ception Therapeutics, Inc.
Ception Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ception Therapeutics, Inc. Develops pharmaceutical products. It focuses on the discovery and development of novel products to address areas of unmet medical need. The company was founded in 2004 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 9 |
Verenigd Koninkrijk | 5 |
Israël | 2 |
Canada | 2 |
China | 2 |
Sectoraal
Health Technology | 9 |
Consumer Services | 5 |
Commercial Services | 2 |
Operationeel
Corporate Officer/Principal | 9 |
Chief Tech/Sci/R&D Officer | 4 |
Director/Board Member | 4 |
Doctorate Degree | 2 |
Undergraduate Degree | 2 |
Sterkste connecties
- Beurs
- Insiders
- Charles J. Davidson
- Bedrijfsconnecties